O'CALLAGHAN BRIAN 4
Research Summary
AI-generated summary
Bolt Biotherapeutics Director Brian O'Callaghan Receives Award
What Happened Brian O'Callaghan, a director of Bolt Biotherapeutics (BOLT), received a derivative award on 2026-06-10: options covering 5,000 shares reported at $0.00 (i.e., a grant/award rather than an open-market purchase). The Form 4 reflecting this grant was filed on 2026-06-11.
Key Details
- Transaction date: 2026-06-10; Form 4 filed: 2026-06-11 (timely).
- Transaction type: Award/Grant of derivative securities (Code A); 5,000 shares @ $0.00.
- Shares owned after transaction: not specified in the provided filing.
- Footnote: options vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting, subject to continuous service; the option vests in full upon a change in control.
- Filing status: appears timely (no late filing flag disclosed).
Context This filing documents a typical director equity grant (an option/award) used for compensation and retention. The award does not represent an immediate market purchase or sale, and vesting conditions mean the shares are not immediately transferable unless accelerated by a change in control.